Ipratropium Bromide

Introduction Overview

Generic Name

ipratropium bromide

Brand Name

Atrovent Nasal

Dosage Form

Nasal solution (nasal spray)

Drug Class

Nasal antihistamines and decongestants

Pharmacokinetics

Absorption:
Ipratropium bromide is poorly absorbed systemically following oral administration, with only approximately 2-3% absorption. Nasally, less than 20% of a typical dose (84 mcg per nostril) is absorbed through the nasal mucosa in both adults and pediatric patients, including those with naturally acquired colds or perennial rhinitis. This limited systemic absorption contributes to a reduced frequency of systemic anticholinergic side effects, enhancing its safety profile for intranasal administration.

Distribution:
In vitro studies show that ipratropium bromide exhibits minimal plasma protein binding, estimated between 0 to 9%, primarily to albumin and α1-acid glycoprotein. The blood to plasma concentration ratio approximates 0.89, indicating moderate distribution between plasma and blood cells. Animal studies, specifically in rats, demonstrate negligible penetration across the blood-brain barrier, accounting for the minimal central nervous system effects observed clinically.

Metabolism:
Ipratropium bromide undergoes partial metabolism via ester hydrolysis, producing inactive metabolites such as tropic acid and tropane. The metabolic pathways have been characterized mostly by in vitro studies utilizing rat brain tissue homogenates, which confirm the inactive nature of these metabolites due to lack of affinity for cholinergic receptors.

Elimination:
Following intravenous administration of 2 mg ipratropium, the elimination half-life is approximately 1.6 hours. Total body clearance is rapid, measured at approximately 2,505 mL/min, with renal clearance accounting for about 1,019 mL/min. Around 50% of the administered intravenous dose is excreted unchanged in the urine within 24 hours. In pediatric patients aged 5-18 years, urinary excretion of unchanged drug post intranasal dosing is approximately 7.8%, comparable to adults. Plasma concentrations remain low post-nasal administration, with negligible accumulation upon repeated dosing. The impact of hepatic or renal impairment on pharmacokinetics has not been specifically studied, necessitating caution in these populations.

Dosage Forms

Available Dosage Forms:
Ipratropium bromide is supplied as a nasal solution in a metered-dose nasal spray device. The commercially available nasal spray concentration is 0.06%, delivering 42 mcg of ipratropium bromide per 70 microliter spray. Each bottle contains 15 mL of solution, which equates to 165 metered sprays per container.

Dosages for Adults and Adolescents:
- For symptomatic relief of rhinorrhea associated with the common cold: Two sprays (84 mcg total) per nostril three to four times daily, leading to a total daily dose ranging from 504 to 672 mcg for adults and adolescents 12 years and older. Dosage adjustment is individualized based on clinical response.
- For seasonal allergic rhinitis: Two sprays (84 mcg) per nostril administered four times daily (total 672 mcg/day) for adults and children 5 years and older.

Dosages for Pediatric Patients:
- Common cold: Children aged 5-11 years may receive two sprays (84 mcg) per nostril three times daily (total 504 mcg/day).
- Seasonal allergic rhinitis: Children aged 5 years and older may receive two sprays per nostril four times daily (total 672 mcg/day).
- Safety and effectiveness in children under 5 years old have not been established.

Specific Patient Populations:
- Use in hepatic or renal impairment has not been studied, but caution is advised.
- No dosage adjustments have been formally recommended due to insufficient pharmacokinetic data.
- Gender does not appear to impact absorption or elimination.

Administration Instructions:
- Initial pump priming requires seven sprays.
- If unused for over 24 hours, two sprays are needed to reprime; if unused for over 7 days, seven sprays are required.
- Avoid spraying into the eyes to prevent ocular adverse effects.

Clinical guidance emphasizes limiting use to 4 days for common cold and 3 weeks for seasonal allergic rhinitis unless otherwise directed by a physician.

Mechanism Of Action

Ipratropium bromide acts primarily as an anticholinergic agent, specifically a competitive antagonist of muscarinic acetylcholine receptors in the nasal mucosa and respiratory tract. By blocking the action of acetylcholine released at parasympathetic nerve terminals, it inhibits vagally-mediated reflexes that stimulate nasal gland secretions. This results in a significant reduction in secretions from serous and seromucous glands lining the nasal mucosa, providing symptomatic relief from rhinorrhea.

At the molecular level, ipratropium bromide, a synthetic quaternary ammonium compound structurally related to atropine, exhibits minimal systemic absorption and poor penetration across lipid membranes such as the blood-brain barrier. Its ionized state at physiological pH limits its access to central nervous system structures, minimizing systemic anticholinergic effects commonly observed with tertiary amines.

Cellular pathways affected include inhibition of M3 muscarinic receptors on glandular secretory cells, thereby decreasing cyclic guanosine monophosphate (cGMP) mediated secretory activity. This anti-secretory effect is localized when administered intranasally, directly reducing nasal discharge without significant impact on nasal congestion or sneezing.

Clinically, this mechanism confers benefits in managing rhinorrhea associated with the common cold and seasonal allergic rhinitis by attenuating excessive nasal secretions. Comparative studies indicate ipratropium’s mechanism is distinct from adrenergic nasal decongestants, which exert vasoconstrictive effects, and from antihistamines that block histamine receptors. The anticholinergic pathway thus represents a targeted approach to controlling nasal secretions with a favorable safety profile confirmed by clinical trials demonstrating rapid onset and duration of symptom improvement.

Pharmacological Actions

Competitive antagonism of muscarinic acetylcholine receptors, primarily M3 subtype, in nasal mucosa leading to decreased secretion.
Local inhibition of vagally-mediated reflex secretions without significant systemic anticholinergic effects due to minimal absorption.
Reduction of rhinorrhea symptoms in common cold and seasonal allergic rhinitis via anti-secretory properties.
Minimal impact on nasal congestion, sneezing, or other allergic symptoms.
Rapid onset of action, frequently observed within one hour of intranasal administration.
Quaternary ammonium structure limits blood-brain barrier penetration, reducing CNS side effects.
Metabolism to inactive ester hydrolysis products limits systemic activity.
No significant effects on cardiovascular or pupillary function at therapeutic doses.
Demonstrated safety in pediatric and adult populations with consistent tolerability profile.
Does not impair mucociliary clearance or nasal physiology according to clinical studies.
Excreted primarily unchanged via renal elimination post systemic absorption.
Additive potential with other anticholinergic agents when co-administered.
No significant pharmacokinetic drug interactions documented.

Therapeutic Or Clinical Uses

Symptomatic relief of rhinorrhea associated with the common cold in adults and children 5 years and older.
Management of rhinorrhea in patients with seasonal allergic rhinitis aged 5 years and older.
Reduction of nasal secretions without affecting nasal congestion or sneezing.
Adjunct treatment option in allergic rhinitis where rhinorrhea predominates.
Used in patients unable to tolerate systemic anticholinergic agents due to low systemic absorption.
Off-label use in other conditions requiring localized anticholinergic action on nasal secretions.
Potential utility in upper respiratory viral infections characterized by excessive nasal discharge.
Suitable for patients requiring fast-acting symptomatic relief of runny nose.
Use in combination with oral antihistamines and decongestants for multi-symptom relief.
Pediatric use supported down to 5 years old for common cold and allergic rhinitis.
Non-systemic administration reduces risk of systemic adverse events compared to oral formulations.
Provides an alternative to nasal decongestants where vasoconstriction is contraindicated.
Compliance is aided by ease of nasal spray delivery system.

Side Or Adverse Effects

Epistaxis (nasal bleeding), reported in approximately 6-8% of patients.
Nasal dryness or irritation causing mild transient discomfort.
Dry mouth or throat sensations following intranasal administration.
Nasal congestion reported rarely, often transient in nature.
Taste perversion including bitter or metallic taste.
Nasal burning or stinging sensations.
Conjunctivitis or ocular irritation due to inadvertent eye exposure.
Coughing or throat irritation post nasal spray administration.
Dizziness and blurred vision reported in rare cases.
Palpitations and tachycardia uncommon but reported during inhalation therapy.
Tinnitus and headache as infrequent systemic side effects.
Hypersensitivity reactions including rash, urticaria, angioedema, and bronchospasm may occur post administration.
No serious adverse events related to nasal dryness or epistaxis requiring discontinuation were reported in trials.
Upper respiratory tract infections may occur as part of symptom complex but not directly linked to drug.
Rare reports of mydriasis, eye pain, and increased intraocular pressure associated with ocular exposure.

Precautions

Use with caution in patients with narrow-angle glaucoma to prevent exacerbation.
Avoid use in patients with prostatic hypertrophy or bladder neck obstruction due to anticholinergic effects.
Not studied in patients with hepatic or renal insufficiency; use cautiously in these populations.
Instruct patients to avoid nasal spray contact with eyes to prevent ocular adverse effects.
Educate patients on proper nasal spray technique including priming and cleaning of device to ensure dosing accuracy.
Patients experiencing blurred vision, eye pain, or visual disturbances should seek medical evaluation promptly.
Advise caution when performing tasks requiring visual acuity or balance (e.g., driving, operating machinery) due to possible dizziness or blurred vision.
Concurrent use with other anticholinergic medications may potentiate systemic side effects.
Safety and effectiveness beyond four days for common cold and three weeks for seasonal allergic rhinitis have not been established.
Pregnancy use only if clearly needed; animal studies show no teratogenicity but human data lacking.
Caution advised when administering to nursing mothers due to unknown excretion into breast milk.
Pediatric use should adhere strictly to recommended dosing; not established in children under 5 years.
Monitor for signs of hypersensitivity reactions and discontinue drug if they occur.
Patients with a history of hypersensitivity to atropine or derivatives should avoid ipratropium.
Advise patients to report nasal bleeding or excessive dryness during treatment.

Warnings

Immediate hypersensitivity reactions including urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema have been reported; discontinue if these occur.
Avoid spraying in or around the eyes to prevent acute angle-closure glaucoma, mydriasis, and ocular discomfort.
Use of ipratropium nasal spray should not exceed four days for common cold or three weeks for seasonal allergic rhinitis without physician guidance.
Patients with narrow-angle glaucoma or urinary retention risk factors should be closely monitored during therapy.
Safety has not been established in patients with renal or hepatic impairment.
May cause temporary blurring of vision and dizziness; caution advised in activities requiring mental alertness.
Post-marketing cases of supraventricular tachycardia and atrial fibrillation reported with oral inhalation formulations in COPD/asthma patients.
Not for systemic use; overdose unlikely by intranasal administration due to limited systemic absorption.
Pump priming instructions must be followed to avoid dosing errors.
Potential additive anticholinergic interactions with concomitant medications.
Pregnancy and lactation use only if clearly needed and after risk-benefit assessment.
Careful patient education needed to reduce risk of ocular exposure.

Contraindication

Known hypersensitivity to ipratropium bromide or atropine and its derivatives.
Hypersensitivity to any inactive ingredients of the nasal spray formulation.
History of allergic reactions to quaternary ammonium compounds.
Avoid in patients with known hypersensitivity reactions to cholinergic antagonists.

Drug Interactions

Potential additive anticholinergic effects when used with other anticholinergic drugs (e.g., oral or inhaled ipratropium, atropine, scopolamine).
No specific pharmacokinetic drug interaction studies have been conducted with ipratropium bromide nasal spray.
Concomitant use with medications causing urinary retention or narrow-angle glaucoma requires caution.
Limited systemic absorption reduces likelihood of systemic drug interactions.
No known interactions with nasal decongestants or antihistamines; often used concurrently for symptom management.
Minimal interaction expected with CYP450 metabolized drugs as ipratropium is not significantly metabolized via this pathway.
Concomitant use with systemic anticholinergics may amplify anticholinergic side effects.
Additive effects on heart rate and blood pressure unlikely but monitoring advised when combined with cardiovascular drugs.
No reported interactions with common cold or allergy medications such as pseudoephedrine or chlorpheniramine.
Care advised if used with drugs that impair mucociliary clearance.

Preparations Of The Drug

Ipratropium Bromide Nasal Solution 0.06% (Nasal Spray): Metered-dose spray delivering 42 mcg per 70 microliter spray.
Packaged in a 15 mL high-density polyethylene bottle containing 165 metered sprays per container.
Formulated as an isotonic aqueous solution, pH adjusted to approximately 4.7.
Contains inactive ingredients: benzalkonium chloride (preservative), edetate disodium dihydrate, sodium chloride, hydrochloric acid and/or sodium hydroxide (for pH adjustment), and purified water.
Equipped with a manual pump spray with safety clip and dust cap to prevent accidental discharge and maintain sterility.
Supplied as prescription-only medication (Rx only).
Storage conditions: Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° to 30°C (59° to 86°F); avoid freezing.
Do not spray into eyes; includes patient instructions for use and cleaning to maintain pump function and dosing accuracy.
Manufactured by Bausch Health Companies Inc., Laval, Quebec, Canada; Distributed by Oceanside Pharmaceuticals, a division of Bausch Health US, LLC.
Packaging includes a carton labeled with NDC 68682-399-15 with clear usage instructions.
Shelf life and expiration dates are per manufacturer labeling, generally 2-3 years from manufacture.
Available primarily as nasal spray; alternative formulations such as inhalation solutions exist but are distinct products.